4,6-Difluromethylisatin | 136622-57-6

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吲哚及其衍生物
• 英文名称: 4,6-Difluromethylisatin
• 英文别名: 4,6-bis(trifluoromethyl)indoline-2,3-dione；4,6-ditrifluoromethyl-1H-indole-2,3-dione；4,6-bis(trifluoromethyl) isatin；4,6-bis(trifluoromethyl)-1H-indole-2,3-dione
• CAS: 136622-57-6
• 化学式: C₁₀H₃F₆NO₂
• 分子量: 283.13
• InChiKey: MHXLRGYCYYYJJB-UHFFFAOYSA-N

物化性质

• 密度：
  1.621±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.5
• 重原子数：
  19
• 可旋转键数：
  0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.2
• 拓扑面积：
  46.2
• 氢给体数：
  1
• 氢受体数：
  8

反应信息

• 作为反应物：
  描述：

  4,6-Difluromethylisatin 在 双氧水 、 sodium hydroxide 作用下， 以 水 为溶剂， 反应 4.0h， 生成 2-amino-4,6-bis(trifluoromethyl)benzoic acid
  参考文献：
  名称：

  [EN] EIF4E-INHIBITING 4-OXO-3,4-DIHYDROPYRIDO[3,4-D]PYRIMIDINE COMPOUNDS
  [FR] COMPOSÉS DE 4-OXO-3,4-DIHYDROPYRIDO[3,4-D]PYRIMIDINE INHIBANT EIF4E

  摘要：

  本发明提供了根据式I合成的化合物、药用可接受的配方和用途，或其立体异构体、互变异构体或药用可接受的盐。对于式I化合物，X1、X2、X3、X4、X5、X6、Q、L1、L2、Y、R1、R2、R3、R4、R5、R6、R7、R8和环A、B和C的定义如规范中所述。创新的式I化合物是eIF4e的抑制剂，并在许多治疗应用中发挥作用，包括但不限于治疗炎症和各种癌症。

  公开号：

  WO2021003157A1
• 作为产物：
  描述：

  N-(3,5-bis(trifluoromethyl)phenyl)formamide 在 氯化亚砜 、 三氯氧磷 作用下， 以 苯 为溶剂， 反应 15.0h， 生成 4,6-Difluromethylisatin
  参考文献：
  名称：

  合成靛红的新方法

  摘要：

  DOI：

  10.1023/a:1017575504084

文献信息

• Imino-Indeno[1,2-c] quinoline derivatives, their preparation processes, and pharmaceutical compositions comprising the same
  申请人：Tzeng Cherng-Chyi

  公开号：US20090111987A1

  公开（公告）日：2009-04-30

  Disclosed herein are novel imino-indeno[1,2-c]quinoline derivatives of formula (I): or a pharmaceutically acceptable salt or solvate thereof, wherein each of the substituents is given the definition as set forth in the Specification and Claims. Also disclosed are the preparation processes of these derivatives, their synthetic precursors and their uses in the manufacture of pharmaceutical compositions for use in the treatment of cancers.

  本文披露了一种新型的imino-indeno[1,2-c]quinoline衍生物，其化学式为(I)：或其药用可接受的盐或溶剂，其中每个取代基的定义如规范和权利要求所述。还披露了这些衍生物的制备过程、它们的合成前体以及它们在制造用于治疗癌症的药物组合物中的用途。
• Isatine derivatives, their preparation and use
  申请人：NEUROSEARCH A/S

  公开号：EP0432648A2

  公开（公告）日：1991-06-19

  A method of treatment with compounds having the formula wherein R¹ is hydrogen, C₁₋₆-alkyl which may be branched, C₃₋₇-cycloalkyl, benzyl, phenyl which may be substituted, acyl, hydroxy, C₁₋₆-alkoxy, CH₂CO₂R' wherein R' is hydrogen or C₁₋₆-alkyl which may be branched, CH₂CN, CH₂CONRIVRV wherein RIV and RV independently are hydrogen or C₁₋₆-alkyl, or CH₂C(=NOH)NH₂; R² is hydrogen, benzyl, C₁₋₆-alkyl which may be branched, or C₃₋₇-cycloalkyl; R⁴, R⁵, R⁶, R⁷ independently are hydrogen, C₁₋₆-alkyl which may be branched, phenyl, halogen, C₁₋₆-alkoxy, NO₂, CN, SO₂NR''R''' wherein R'' and R''' independently are hydrogen or C₁₋₆-alkyl, or CF₃; or R⁶ and R⁷ together form an additional 4 to 7 membered ring which may be aromatic or partial saturated and which may be substituted with halogen, NO₂, CF₃, CN, SO₂NR''R''' wherein R'' and R''' independently are hydrogen or C₁₋₆-alkyl, and R⁴ and R⁵ have the meanings set forth above, are disclosed, as well as pharmaceutical compositions thereof. Certain of the compounds are novel. The compounds and pharmaceutical compositions containing the compounds are useful in the treatment of central nervous system disorders and especially conditions sensitive to excitatory amino acids.

  一种用具有以下式子的化合物进行处理的方法 其中 R¹ 是氢、C₁₋₆-烷基（可以是支链）、C₃₋₇-环烷基、苄基、苯基（可以是取代的）、酰基、羟基、C₁₋₆-烷氧基、CH₂CO₂R'，其中 R' 为氢或 C₁₋₆- 烷基（可为支链）、CH₂CN、CH₂CONRIVRV，其中 RIV 和 RV 独立地为氢或 C₁₋₆- 烷基，或 CH₂C(=NOH)NH₂； R² 是氢、苄基、C₁₋₆-烷基（可以是支链）或 C₃₋₇-环烷基； R⁴、R⁵、R⁶、R⁷各自为氢、C₁₋₆-烷基（可为支链）、苯基、卤素、C₁₋₆-烷氧基、NO₂、CN、SO₂NR''R'''（其中 R'' 和 R''' 各自为氢或 C₁₋₆-烷基）或 CF₃；或 R⁶ 和 R⁷ 共同形成另外一个 4 至 7 个成员的环，该环可以是芳香族或部分饱和环，可以被卤素、NO₂、CF₃、CN、公开了 SO₂NR''R'''，其中 R'' 和 R''' 独立地为氢或 C₁₋₆ 烷基，且 R⁴ 和 R⁵ 具有上述含义，还公开了其药物组合物。其中某些化合物是新颖的。 这些化合物和含有这些化合物的药物组合物可用于治疗中枢神经系统疾病，特别是对兴奋性氨基酸敏感的疾病。
• Hydrazone derivatives, their preparation and use
  申请人：NEUROSEARCH A/S

  公开号：EP0503349A1

  公开（公告）日：1992-09-16

  A method of treatment with compounds having the formula wherein n is 0 or 1; R¹ is hydrogen, C₁₋₆-alkyl which may be branched, C₃₋₇-cycloalkyl, benzyl, phenyl which may be substituted, acyl, hydroxy, C₁₋₆-alkoxy, CH₂CO₂R' wherein R' is hydrogen or C₁₋₆-alkyl which may be branched, CH₂CN, CH₂CONRIVRV wherein RIV and RV independently are hydrogen or C₁₋₆-alkyl, or CH₂C(=NOH)NH₂; R² is pyridyl or phenyl, both of which may be substituted one or more times preferably in the ortho and para positions with halogen, CF₃, NO₂, CN, phenyl, SO₂NR''R''' wherein R'' and R''' independently are hydrogen, benzyl, or C₁₋₆-alkyl; R⁴, R⁵, R⁶, R⁷ independently are hydrogen, C₁₋₆-alkyl which may be branched, phenyl, halogen, C₁₋₆-alkoxy, NO₂, CN, CF₃, or SO₂NR¹¹R¹² wherein R¹¹ and R¹² independently are hydrogen, benzyl, or C₁₋₆-alkyl; or R⁶ and R⁷ together form an additional 4 to 8 membered carbocyclic ring which may be aromatic or partial saturated and which may be substituted with halogen, NO₂, CF₃, CN, SO₂NR¹³R¹⁴ wherein R¹³ and R¹⁴ independently are hydrogen, benzyl, or C₁₋₆-alkyl, and R⁴ and R⁵ have the meanings set forth above; or R⁴ and R⁵ together form an additional 4 to 8 membered carbocyclic ring which may be aromatic or partial saturated and which may be substituted with halogen, NO₂, CF₃, CN, SO₂NR¹³R¹⁴ wherein R¹³ and R¹⁴ independently are hydrogen, benzyl, or C₁₋₆-alkyl, and R⁶ and R⁷ have the meanings set forth above. Certain of the compounds are novel. The compounds and pharmaceutical compositions containing the compounds are useful in the treatment of central nervous system disorders and especially conditions sensitive to excitatory amino acids.

  一种用具有以下式子的化合物进行处理的方法 其中 n 是 0 或 1； R¹ 是氢、C₁₋₆-烷基（可为支链）、C₃₋₇-环烷基、苄基、苯基（可被取代）、 酰基、羟基、C₁₋₆-烷氧基、CH₂CO₂R'（其中 R'为氢或 C₁₋₆- 烷基，可为支链）、CH₂CN、CH₂CONRIVRV（其中 RIV 和 RV 独立地为氢或 C₁₋₆-烷基）或 CH₂C(=NOH)NH₂； R² 是吡啶基或苯基，二者最好在正位和对位被卤素、CF₃、NO₂、CN、苯基、SO₂NR''R'''取代一次或多次，其中 R'' 和 R'''' 独立地为氢、苄基或 C₁₋₆-烷基； R⁴、R⁵、R⁶、R⁷ 各自为氢、C₁₋₆-烷基（可为支链）、苯基、卤素、C₁₋₆-烷氧基、NO₂、CN、CF₃或 SO₂NR¹R¹²，其中 R¹ 和 R¹² 独立地是氢、苄基或 C₁₋₆-烷基；或 R⁶ 和 R⁷ 共同形成另外一个 4 至 8 个成员的碳环，该碳环可为芳香族或部分饱和环，可被卤素、NO₂、CF₃、CN、SO₂NR¹³R¹⁴，其中 R¹³ 和 R¹⁴ 独立为氢、苄基或 C₁₋₆ 烷基，且 R⁴ 和 R⁵ 具有上述含义； 或 R⁴ 和 R⁵ 共同形成一个额外的 4 至 8 位碳环，该碳环可为芳香族或部分饱和环，可被卤素、NO₂、CF₃、CN、SO₂NR¹³R¹⁴，其中 R¹³ 和 R¹⁴ 独立地为氢、苄基或 C₁₋₆ 烷基，且 R⁶ 和 R⁷ 具有上述含义。 某些化合物具有新颖性。 这些化合物和含有这些化合物的药物组合物可用于治疗中枢神经系统疾病，特别是对兴奋性氨基酸敏感的疾病。
• Synthesis and Structure−Activity Relationships of 3-Aryloxindoles:  A New Class of Calcium-Dependent, Large Conductance Potassium (Maxi-K) Channel Openers with Neuroprotective Properties
  作者：Piyasena Hewawasam、Matthew Erway、Sandra L. Moon、Jay Knipe、Harvey Weiner、Christopher G. Boissard、Debra J. Post-Munson、Qi Gao、Stella Huang、Valentin K. Gribkoff、Nicholas A. Meanwell

  DOI：10.1021/jm0101850

  日期：2002.3.1

  A series of 3-aryloxindole derivatives were synthesized and evaluated as activators of the cloned maxi-K channel mSlo expressed in Xenopus laevis oocytes using electrophysiological methods. The most promising maxi-K openers to emerge from this study were (+/-)-3(5-chloro-2-hydroxyphenyl)-1,3-dihydro-3-hydroxy-6-(trifluoromethyl)-2H-indol-2-one ((+/-)-8c) and its 3-deshydroxy analogue (+/-)-11b. The individual enantiomers of (+/-)-8c were synthesized, and the maxi-K channel-opening properties were shown to depend on the absolute configuration of the single stereogenic center with the efficacy of (-)-8c superior to that of both (+)-8c and the racemic mixture when evaluated at a concentration of 20 muM. Racemic 11b exhibited greater efficacy than either the racemic Se or the more active enantiomer in the electrophysiological evaluation. In vitro metabolic stability studies conducted with (+/-)-8c and (+/-)-11b in rat liver S9 microsomal fractions revealed significant oxidative degradation with two hydroxylated metabolites observed by liquid chromatography/mass spectrometry for each compound in addition to the production of Se from 11b. The pharmacokinetic properties of (+/-)-8c and (+/-)11b were determined in rats as a prelude to evaluation in a rat model of stroke that involved permanent occlusion of the middle cerebral artery (MCAO model). In the MCAO model, conducted in the spontaneously hypertensive rat, the more polar 3-hydroxy derivative (+/-)-8c did not demonstrate a significant reduction in cortical infarct volume when administered intravenously at doses ranging from 0.1 to 10 mg/kg as a single bolus 2 h after middle cerebral artery occlusion when compared to vehicle-treated controls. In contrast, intravenous administration of (+/-)-11b at a dose of 0.03 mg/kg was found to reduce the measured cortical infarct volume by approximately 18% when compared to vehicle-treated control animals. Intraperitoneal administration of (+/-)-11b at a dose of 10 mg/kg 2 h following artery occlusion was shown to reduce infarct volume by 26% when compared to vehicle-treated controls. To further probe the effects of compounds (+/-)-8c and (+/-)-11b on neurotransmitter release in vitro, both compounds were examined for their ability to reduce electrically stimulated [H-3]-glutamate release from rat hippocampal slices that had been preloaded with [H-3]-glutamate. Only (+/-) 11b was able to demonstrate a significant inhibition [3H]-glutamate release in this assay at a concentration of 20 muM, providing concordance with the profile of these compounds in the MCAO model. Although (+/-)-11b showed some promise as a potential developmental candidate for the treatment of the sequelae of stroke based on its efficacy in the rat MCAO model, the pharmacokinetic profile of this compound was considered to be less than optimal and was not pursued in favor of derivatives with enhanced metabolic stability.
• 3-Substituted oxindole derivatives as potassium channel modulators
  申请人：BRISTOL-MYERS SQUIBB COMPANY

  公开号：EP0747354B1

  公开（公告）日：2000-08-16